[go: up one dir, main page]

ES2150493T3 - Adyuvantes para vacunas contra el virus sincitico respiratorio. - Google Patents

Adyuvantes para vacunas contra el virus sincitico respiratorio.

Info

Publication number
ES2150493T3
ES2150493T3 ES94918109T ES94918109T ES2150493T3 ES 2150493 T3 ES2150493 T3 ES 2150493T3 ES 94918109 T ES94918109 T ES 94918109T ES 94918109 T ES94918109 T ES 94918109T ES 2150493 T3 ES2150493 T3 ES 2150493T3
Authority
ES
Spain
Prior art keywords
synctic
adjuvants
viruses
vaccines against
against respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918109T
Other languages
English (en)
Other versions
ES2150493T5 (es
Inventor
Gerald E Hancock
Dan J Speelman
Patrick J Frenchick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22078872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150493(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2150493T3 publication Critical patent/ES2150493T3/es
Publication of ES2150493T5 publication Critical patent/ES2150493T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULACIONES DE VACUNAS Y METODOS TERAPEUTICOS PARA LAS MISMAS QUE CONTIENEN PROTEINAS VIRALES SINCITIALES RESPIRATORIAS O FRAGMENTOS INMUNOLOGICOS Y ADJUTORES SELECCIONADOS DE UN GRUPO QUE CONSISTE DE QS-21, MONOFOSFORIL LIPIDO A 3-DEACILATADO, MONOFOSFORIL LIPIDO A Y UNA COMBINACION. LA PRESENCIA DE LOS ADJUTORES INCREMENTA CONSIDERABLEMENTE LA INMUNOGENICIDAD HUMORAL Y CELULA-MEDIADA DE LAS PROTEINAS RSV.
ES94918109T 1993-05-25 1994-05-24 Adyuvantes para vacunas contra el virus sincitico respiratorio. Expired - Lifetime ES2150493T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6785593A 1993-05-25 1993-05-25
US67855 1993-05-25

Publications (2)

Publication Number Publication Date
ES2150493T3 true ES2150493T3 (es) 2000-12-01
ES2150493T5 ES2150493T5 (es) 2004-07-01

Family

ID=22078872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918109T Expired - Lifetime ES2150493T5 (es) 1993-05-25 1994-05-24 Adyuvantes para vacunas contra el virus sincitico respiratorio.

Country Status (15)

Country Link
US (1) US5723130A (es)
EP (1) EP0705109B2 (es)
JP (1) JP3734263B2 (es)
AT (1) ATE196737T1 (es)
AU (1) AU676340B2 (es)
CA (1) CA2163550A1 (es)
DE (1) DE69426077T3 (es)
DK (1) DK0705109T4 (es)
ES (1) ES2150493T5 (es)
FI (1) FI955667L (es)
GR (1) GR3034785T3 (es)
NO (1) NO954786L (es)
PT (1) PT705109E (es)
RU (1) RU2160119C2 (es)
WO (1) WO1994027636A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE322289T1 (de) * 1994-10-05 2006-04-15 Univ Vanderbilt Interleukin-12 als adjuvans für paramyoxviridae impfstoffe
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6975708B1 (en) 1996-04-17 2005-12-13 Convergys Cmg Utah, Inc. Call processing system with call screening
US5867562A (en) * 1996-04-17 1999-02-02 Scherer; Gordon F. Call processing system with call screening
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
WO1998002180A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
DK1126876T3 (da) * 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
AU4040200A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540171A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
ID30407A (id) * 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7374751B1 (en) * 2000-06-22 2008-05-20 Wyeth Holdings Corporation QS-21 and IL-12 as an adjuvant combination
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
GEP20074077B (en) * 2000-11-10 2007-03-26 Wyeth Corp Antigenic composition
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE10205373B4 (de) * 2002-02-09 2007-07-19 Aloys Wobben Brandschutz
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
US20060095001A1 (en) * 2004-10-29 2006-05-04 Transcutaneous Technologies Inc. Electrode and iontophoresis device
ES2434732T3 (es) * 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
JP2006346368A (ja) * 2005-06-20 2006-12-28 Transcutaneous Technologies Inc イオントフォレーシス装置及びその製造方法
JP2007000342A (ja) * 2005-06-23 2007-01-11 Transcutaneous Technologies Inc 複数薬剤の投与量および投与時期を制御するイオントフォレーシス装置
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8295922B2 (en) 2005-08-08 2012-10-23 Tti Ellebeau, Inc. Iontophoresis device
US20070088332A1 (en) * 2005-08-22 2007-04-19 Transcutaneous Technologies Inc. Iontophoresis device
JPWO2007023907A1 (ja) * 2005-08-24 2009-02-26 Ｔｔｉ・エルビュー株式会社 冷凍型イオントフォレーシス用電極構造体
JPWO2007026672A1 (ja) * 2005-08-29 2009-03-05 Ｔｔｉ・エルビュー株式会社 イオントフォレーシス用汎用性電解液組成物
US20100030128A1 (en) * 2005-09-06 2010-02-04 Kazuma Mitsuguchi Iontophoresis device
US20070112294A1 (en) * 2005-09-14 2007-05-17 Transcutaneous Technologies Inc. Iontophoresis device
CN101252968A (zh) * 2005-09-15 2008-08-27 Tti优而美株式会社 棒式离子电渗疗装置
CA2619661A1 (en) * 2005-09-16 2007-03-22 Tti Ellebeau, Inc. Catheter-type iontophoresis device
WO2007037324A1 (ja) * 2005-09-28 2007-04-05 Transcu Ltd. 乾燥型イオントフォレーシス用電極構造体
KR20080066712A (ko) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
JP2009509634A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 官能基化マイクロニードル経皮薬剤送達システム、装置及び方法
WO2007041323A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of vesicle-encapsulated active agents
WO2007041314A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
WO2007041115A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau Inc. Method and system to detect malfunctions in an iontophoresis device that delivers active agents to biological interfaces
JP4902543B2 (ja) * 2005-09-30 2012-03-21 Ｔｔｉ・エルビュー株式会社 形状記憶セパレータを有するイオントフォレーシス用電極構造体およびそれを用いたイオントフォレーシス装置
EP1944057A4 (en) * 2005-09-30 2009-02-18 Tti Ellebeau Inc IONTOPHORESIS DEVICE FOR MONITORING THE DOSE AND TIME OF ADMINISTRATION OF A SLEEP-INDUCING AND ANALYTICAL AGENT
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
EP1931420A2 (en) * 2005-09-30 2008-06-18 Tti Ellebeau, Inc. Iontophoresis device to deliver multiple active agents to biological interfaces
US20070197955A1 (en) * 2005-10-12 2007-08-23 Transcutaneous Technologies Inc. Mucous membrane adhesion-type iontophoresis device
WO2007079116A1 (en) * 2005-12-28 2007-07-12 Tti Ellebeau, Inc. Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
KR20090064422A (ko) * 2006-09-05 2009-06-18 티티아이 엘뷰 가부시키가이샤 유도 전원 공급기들을 사용하는 경피성 약물 전달 시스템, 장치, 및 방법
TW200838576A (en) 2006-12-01 2008-10-01 Transcu Ltd Systems, devices and methods for powering and/or controlling transdermal delivery devices
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2703667C (en) * 2007-10-25 2015-12-29 Lawrence M. Kauvar Anti-rsv g protein antibodies
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20100312168A1 (en) * 2009-06-09 2010-12-09 Yoshimasa Yoshida Long life high capacity electrode, device, and method of manufacture
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
US9433671B2 (en) 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
EP3349788A4 (en) 2015-09-16 2019-06-05 Artificial Cell Technologies, Inc. Antimalarial Compositions and Methods
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
US20210290754A1 (en) * 2018-08-07 2021-09-23 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814386B (en) † 1980-07-01 1982-07-28 Nat Res Dev Production of viral antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
KR0137963B1 (ko) * 1987-12-23 1998-04-30 로버트 에이. 아미테이지 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9120221D0 (en) † 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen

Also Published As

Publication number Publication date
DK0705109T4 (da) 2004-05-10
AU6957194A (en) 1994-12-20
EP0705109A1 (en) 1996-04-10
AU676340B2 (en) 1997-03-06
DE69426077T3 (de) 2004-09-02
EP0705109B2 (en) 2004-01-02
DE69426077D1 (de) 2000-11-09
FI955667L (fi) 1996-01-12
DE69426077T2 (de) 2001-05-10
ES2150493T5 (es) 2004-07-01
JPH08510749A (ja) 1996-11-12
CA2163550A1 (en) 1994-12-08
PT705109E (pt) 2001-02-28
DK0705109T3 (da) 2000-11-13
RU2160119C2 (ru) 2000-12-10
ATE196737T1 (de) 2000-10-15
FI955667A0 (fi) 1995-11-24
EP0705109A4 (en) 1998-09-02
WO1994027636A1 (en) 1994-12-08
JP3734263B2 (ja) 2006-01-11
EP0705109B1 (en) 2000-10-04
GR3034785T3 (en) 2001-02-28
NO954786D0 (no) 1995-11-24
US5723130A (en) 1998-03-03
NO954786L (no) 1996-01-23

Similar Documents

Publication Publication Date Title
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
HU9904549A (en) Vaccines
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
HUP9802819A2 (hu) Hősokkfehérje-alapú oltóanyagok és immunterápiák
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
ES2158108T3 (es) Vacunacion in ovo contra la coccidiosis.
DK0745387T3 (da) Adjuvanser til virale vacciner
PE97298A1 (es) Composicion para vacunas
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DE69531793D1 (de) Immunogene zubereitungen
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
BR9604853A (pt) Vacinas contra chlamydia
CO5300406A1 (es) Vacuna
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
OA09037A (en) Prevention and treatement of retroviral disease.
ES2059305T3 (es) Proteina del virus de la seudorrabia.
ES500199A0 (es) Un procedimiento para preparar una vacuna de virus de la ra-bia inactivados
ES2055610T3 (es) Vacuna contra hrsv.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.
FR2648712B1 (fr) Vaccin contre le virus de la leucemie bovine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 705109

Country of ref document: ES